S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
S&P 500   5,263.28 (+0.28%)
DOW   39,856.47 (+0.24%)
QQQ   444.84 (+0.00%)
AAPL   171.91 (-0.81%)
MSFT   421.14 (-0.07%)
META   489.12 (-0.96%)
GOOGL   151.14 (+0.18%)
AMZN   180.49 (+0.37%)
TSLA   176.03 (-2.11%)
NVDA   906.01 (+0.39%)
NIO   4.50 (-3.64%)
AMD   180.24 (+0.36%)
BABA   72.42 (+1.16%)
T   17.65 (+0.57%)
F   13.24 (+1.38%)
MU   117.92 (-1.02%)
CGC   8.61 (-9.84%)
GE   175.73 (-2.44%)
DIS   122.29 (+1.08%)
AMC   3.66 (-15.67%)
PFE   27.85 (+0.25%)
PYPL   67.17 (+0.90%)
XOM   116.14 (+1.02%)
NASDAQ:RCM

R1 RCM (RCM) Stock Price, News & Analysis

$12.96
-0.04 (-0.31%)
(As of 03:16 PM ET)
Today's Range
$12.91
$13.31
50-Day Range
$9.96
$14.58
52-Week Range
$8.87
$18.70
Volume
2.21 million shs
Average Volume
4.15 million shs
Market Capitalization
$5.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.35

R1 RCM MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
32.8% Upside
$17.35 Price Target
Short Interest
Healthy
8.26% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.27mentions of R1 RCM in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$143,959 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.04) to $0.15 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.90 out of 5 stars

Business Services Sector

7th out of 311 stocks

Management Services Industry

1st out of 5 stocks

RCM stock logo

About R1 RCM Stock (NASDAQ:RCM)

R1 RCM Inc. provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers. The company also offers modular solutions, including functional partnership, an outsourcing solutions for improvements across targeted revenue cycle areas for hospital and physician group customers; revenue recovery, to fast-track payer and patient cash collections; revenue optimization, a solution to uncover missed or underreported revenue; clinical integrity, used to improve documentation and coding accuracy to maximize earned revenue for the services provided; and regulatory navigation, a compliance-first solutions for government reimbursement accuracy, pharmacy savings, and compliance. The company was incorporated in 2003 and is headquartered in Murray, Utah.

RCM Stock Price History

RCM Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
R1 RCM (NASDAQ:RCM) Given Overweight Rating at Morgan Stanley
Citigroup Upgrades R1 RCM (NASDAQ:RCM) to "Buy"
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Analyst Scoreboard: 12 Ratings For R1 RCM
RCM Apr 2024 20.000 call
R1 RCM just downgraded at Citi, here's why
See More Headlines
Receive RCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for R1 RCM and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/16/2023
Today
3/28/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Management services
Sub-Industry
Health Care Services
Current Symbol
NASDAQ:RCM
CUSIP
00438V10
Employees
30,000
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$17.35
High Stock Price Target
$22.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+31.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
16 Analysts

Profitability

Net Income
$3.30 million
Pretax Margin
0.93%

Debt

Sales & Book Value

Annual Sales
$2.25 billion
Cash Flow
$0.70 per share
Book Value
$6.56 per share

Miscellaneous

Free Float
264,776,000
Market Cap
$5.55 billion
Optionable
Optionable
Beta
0.79

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Lee  RivasMr. Lee Rivas (Age 49)
    CEO & Director
    Comp: $1.12M
  • Mr. John M. SparbyMr. John M. Sparby (Age 48)
    President
    Comp: $656.99k
  • Ms. Jennifer Williams (Age 47)
    Executive VP, CFO & Treasurer
  • Ms. Pamela L. Spikner (Age 47)
    Principal Accounting Officer & Chief Accounting Officer
  • Evan Smith C.F.A.
    Senior Vice President of Finance & Investor Relations
  • Mr. Corey Perman
    Executive Vice President of Compliance & Risk
  • Mr. Sean Radcliffe
    Executive VP, General Counsel & Corporate Secretary
  • Ms. Kate Sanderson
    Executive VP & Chief Human Resources Officer
  • Mr. David Strickle
    Executive Vice President of Integration
  • Mr. Kyle A. Hicok (Age 44)
    Executive VP & Chief Commercial Officer

RCM Stock Analysis - Frequently Asked Questions

Should I buy or sell R1 RCM stock right now?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for R1 RCM in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RCM shares.
View RCM analyst ratings
or view top-rated stocks.

What is R1 RCM's stock price target for 2024?

16 analysts have issued 12-month target prices for R1 RCM's stock. Their RCM share price targets range from $11.00 to $22.00. On average, they anticipate the company's share price to reach $17.35 in the next twelve months. This suggests a possible upside of 32.8% from the stock's current price.
View analysts price targets for RCM
or view top-rated stocks among Wall Street analysts.

How have RCM shares performed in 2024?

R1 RCM's stock was trading at $10.57 on January 1st, 2024. Since then, RCM stock has increased by 23.7% and is now trading at $13.07.
View the best growth stocks for 2024 here
.

Are investors shorting R1 RCM?

R1 RCM saw a drop in short interest in March. As of March 15th, there was short interest totaling 12,440,000 shares, a drop of 28.9% from the February 29th total of 17,490,000 shares. Based on an average daily volume of 4,040,000 shares, the short-interest ratio is currently 3.1 days. Approximately 8.3% of the company's stock are sold short.
View R1 RCM's Short Interest
.

When is R1 RCM's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our RCM earnings forecast
.

How were R1 RCM's earnings last quarter?

R1 RCM Inc. (NASDAQ:RCM) posted its earnings results on Thursday, February, 16th. The healthcare provider reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.06. The healthcare provider earned $532.80 million during the quarter, compared to the consensus estimate of $519.28 million. R1 RCM had a trailing twelve-month return on equity of 0.12% and a net margin of 0.15%. The company's revenue was up 33.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.11 earnings per share.

What guidance has R1 RCM issued on next quarter's earnings?

R1 RCM issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.6 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

What is Joseph Flanagan's approval rating as R1 RCM's CEO?

253 employees have rated R1 RCM Chief Executive Officer Joseph Flanagan on Glassdoor.com. Joseph Flanagan has an approval rating of 70% among the company's employees.

What other stocks do shareholders of R1 RCM own?

Based on aggregate information from My MarketBeat watchlists, some companies that other R1 RCM investors own include NVIDIA (NVDA), JD.com (JD), Baozun (BZUN), Inseego (INSG), BioXcel Therapeutics (BTAI), Marvell Technology (MRVL), Akoustis Technologies (AKTS), Alibaba Group (BABA), Bilibili (BILI) and Model N (MODN).

Who are R1 RCM's major shareholders?

R1 RCM's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (3.62%), Vanguard Group Inc. (3.62%), Capital International Investors (1.99%), Voss Capital LLC (1.70%), Norges Bank (0.96%) and P2 Capital Partners LLC (0.84%). Insiders that own company stock include Achi Series Lllp Tcp-Asc, Alex Mandl, Gary Steven Long, John B Henneman III, John M Sparby, Joseph Gerard Flanagan, Lee Rivas and Richard B Jr Evans.
View institutional ownership trends
.

How do I buy shares of R1 RCM?

Shares of RCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does R1 RCM have any subsidiaries?
The following companies are subsidiares of R1 RCM: Accretive Health Mauritius Inc., Cerner RevWorks, Clearsight Intermediate Holdings Inc., Cloudmed, Flare Capital Partners Investment Company, Intermedix, Intermedix ARM LLC, Intermedix Corporation, Intermedix Holdings Inc., Intermedix Lietuva UAB, Intermedix Midco Inc., Intermedix Office Based LLC, Intermedix Staffing Inc., Medical Consultants Inc., Practice Support Resources LLC, Project Links Parent Inc., Project Roadrunner Merger Sub Inc., Project Roadrunner Parent Inc., R1 RCM Global Private Limited, R1 RCM India Private Limited, Rover16 Inc., SCHEDULING.COM INC., SCI Solutions, Tonic Health LLC, VisitPay, cGate Health Inc., and iVinci Partners LLC.
Read More
This page (NASDAQ:RCM) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners